Abstract: A method is described for inhibiting IgE production which comprises administering, in an amount effective to inhibit IgE production, a prostaglandin of the formula: ##STR1## or a pharmaceutically acceptable non-toxic salt thereof, in which R is hydrogen, C.sub.1 -C.sub.5 alkyl, C.sub.3 -C.sub.8 cycloalkyl, phenyl, or mono, di- or tri-substituted phenyl in which the substituents are selected form the group consisting of bromo, chloro, fluoro, iodo, C.sub.1 -C.sub.5 alkyl, hydroxy, nitro, acetyl, alkoxy, carboxy, acetoxy, amino, mono- or di- alkyl amino, amido and acetamido; R.sub.1 and R.sub.2 independently are hydrogen or C.sub.1 -C.sub.5 alkyl, n.sub.3, n.sub.4, n.sub.5, n.sub.6, n.sub.7, and n.sub.8 independently are zero or one; when n's are zeros, R.sub.3 and R.sub.4 together, R.sub.4 and R.sub.5 together, R.sub.5 and R.sub.6 together, and R.sub.7 and R.sub.8 together are double bonds; when n's are ones, R.sub.3, R.sub.5, R.sub.6 R.sub.7 and R.sub.8 independently are hydrogen, R.sub.

Abstract: A method is described for inhibiting IgE production which comprises administering, in an amount effective to inhibit IgE production, a prostaglandin of the formula: ##STR1## or a pharmaceutically acceptable non-toxic salt thereof, in which R is hydrogen, C.sub.1 -C.sub.5 alkyl, C.sub.3 -C.sub.8 cycloalkyl, phenyl, or mono, di- or tri-substituted phenyl in which the substituents, are selected from the group consisting of bromo, chloro, fluoro, iodo, C.sub.1 -C.sub.5 alkyl, hydroxy, nitro, acetyl, alkoxy, carboxy, acetoxy, amino, mono- or di- alkyl amino, amido and acetamido; R.sub.1 and R.sub.2 independently are hydrogen or C.sub.1 -C.sub.5 alkyl, n.sub.3, n.sub.4, n.sub.5, n.sub.6, n.sub.7, and n.sub.8 independently are zero or one; when n's are zeros, R.sub.3 and R.sub.4 together, R.sub.4 and R.sub.5 together, R.sub.5 and R.sub.6 together, and R.sub.7 and R.sub.8 together are double bonds; when n's are ones, R.sub.3, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 independently are hydrogen, R.sub.